Improving outcomes for people with cystic fibrosis through evidence based clinical trials

      Impact: Health Impact, Quality of Life Impact

      View graph of relations

      Narrative

      New therapies supported by clear evidence from clinical trials have resulted in outstanding improvements in survival and quality of life for people living with cystic fibrosis (CF). Elborn’s clinical trials group has delivered a programme of crucial clinical trials which has impacted on clinical practice in CF. From 2009-2012 Elborn co-led a pivotal multicentre trial using Ivacaftor (Kalydeco TM), a transformative new drug which represents a paradigm shift as the first approved therapy that corrects the basic defect in CF. This therapy is an exemplar of personalised medicine and is prescribed for patients with the specific gene mutation in which this drug works.

      Category of impact

      • Health Impact
      • Quality of Life Impact

      ID: 13039256